La Jolla Pharmaceutical Company Revenue and Competitors

Location

$190.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • La Jolla Pharmaceutical Company's estimated annual revenue is currently $15M per year.(i)
  • La Jolla Pharmaceutical Company's estimated revenue per employee is $153,061
  • La Jolla Pharmaceutical Company's total funding is $190.9M.

Employee Data

  • La Jolla Pharmaceutical Company has 98 Employees.(i)
  • La Jolla Pharmaceutical Company grew their employee count by -16% last year.

La Jolla Pharmaceutical Company's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is La Jolla Pharmaceutical Company?

La Jolla Pharmaceutical Company (LJPC) is a biopharmaceutical company that is focused on the research and development of highly specific therapeutics for the treatment of certain life-threatening antibody-mediated diseases. These diseases, including autoimmune conditions such as lupus and antibody-mediated stroke, are caused by abnormal B cell production of antibodies that attack healthy tissues. The Company\'s drug candidates, called Toleragens, are designed to treat the underlying cause of many antibody-mediated diseases without the severe, adverse side effects common to other treatments. The Company is analyzing data from a Phase III clinical trial of its lupus drug candidate, LJP 394, and its clinical drug candidate for the treatment of antibody-mediated thrombosis, known as LJP 1082, is currently being evaluated in toxicology studies that are required prior to the initiation of clinical trials.

keywords:N/A

$190.9M

Total Funding

98

Number of Employees

$15M

Revenue (est)

-16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

La Jolla Pharmaceutical Company News

2022-04-20 - Thalassemia Market Size, Outlook And Forecast | Bluebird bio ...

... GlaxoSmithKline plc, Incyte Corporation, Gamida Cell, Kiadis Pharma, La Jolla Pharmaceutical Company, IONIS Pharmaceuticals.

2022-04-20 - Activin Receptor Type 1 Market Size 2022-2029| Key Players ...

Daiichi Sankyo Company Ltd; La Jolla Pharmaceutical Company; Oncodesign Sa; Tolero Pharmaceuticals Inc … Activin Receptor Type 1 Market Breakdown by Type: Ljpc...

2022-04-20 - Acid Sphingomyelinase Deficiency Drug Market Size 2022 ...

... Genzyme Corporation, La Jolla Pharmaceutical Company, Merck & Co., Inc. ... vendor landscape and important company profiles,medical disposable market...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27M98-7%$19.5M
#2
$34.6M982%N/A
#3
$16M985%N/A
#4
$15.2M98-4%$156.1M
#5
$14.7M988%N/A